WARNING: This list was made prior to the version 4 release of TDR
Targets (Aug, 2010). Some queries included in this list may not work properly.
Most likely reasons for this are changes in parameters, and/or data updates. If you
experience any problem, please try re-running each search from the search
page. You can also access the previous version of the database at
For this genome prioritization we considered several filters independently and calculated the weighted (ranked) UNION of these, so we don`t exclude targets that miss some of the criteria. We considered lethal and some non-lethal mutant phenotypes in C. elegans and D. melanogaster or in ANY species (although non-lethals have a lower weight); expression data from ESTs obtained from SchistoDB (expressed in ANY relevant stage, but also giving a higher weight if expressed in more than one relevant stage); druggability inferred by sequence similarity against known druggable targets; availability of structural models in Modbase; and gave a negative weight to the presence of orthologous genes in human.
D. melanogaster knock-out phenotypes were downloaded from FlyBase, and mapped to Schistosoma mansoni genes through OrthoMCL clusters. EST data was obtained from SchistoDB.
I have also included the top targets list from Caffrey et al.: the top 35 targets (with orthologs in D.melanogaster AND C.elegans, with deleterious mutant phenotypes in these model organisms, expressed in relevant stages, and orthologs to known druggable genes described in literature), and top 18 targets (which are also homologous to proteins with 3d structures including co-crystallized ligands).
These two lists have not been given a weight so: i) they don't affect our prioritization but ii) they appear in the final list so we can see where they rank in our list.
A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. (2009).
PLoS ONE 4: